Validation of blood-based biomarkers of alzheimer's disease to monitor amyloid clearance in the treatment clinic

Active Cooperative Agreement Awarded

Award ID
U01AG103014
Recipient
Awarding agency
Obligated
$803,175

Award facts

Assistance listing
93.866 Aging Research
Completion date 4% complete
Place of performance
San Francisco, CA 94143, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute on Aging, awarded $803,175 to The Regents of the University of California, San Francisco, acting through its Controller's Office, under Cooperative Agreement U01AG103014 on September 9, 2026. The award falls under the Aging Research program (CFDA 93.866), which supports biomedical, social, and behavioral research on the aging process and its diseases, with emphasis on Alzheimer's disease and related dementias.

The award funds validation of blood-based biomarkers, specifically plasma p-tau217 and Aβ42, as surrogates for amyloid PET in patients receiving donanemab, to guide treatment discontinuation decisions. Aim 1 calibrates amyloid plaque clearance measured on PET against longitudinal biomarker trajectories in 250 patients treated with donanemab, and the project hypothesizes that biomarker changes will predict amyloid clearance with greater than 90% accuracy. Aim 2 tests the biomarkers prospectively as a monitoring tool to identify patients likely to have cleared plaques, triggering confirmatory PET and treatment discontinuation when appropriate. Blood samples will be banked to create a biorepository for future biomarker discovery.

The study spans four sites in Northern California, and the award's place of performance is San Francisco, California 94143. The period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2031.

Description

Abstract
The approval and implementation of amyloid-targeting antibodies for alzheimer's disease (ad), including donanemab, has transformed treatment but raised new implementation challenges. Donanemab is unique in that therapy is intended to stop once amyloid plaques are cleared, which occurs in about 70% of patients within one year. In clinical trials, amyloid clearance was assessed every six months with amyloid pet, but this approach is costly, burdensome, and inaccessible in real-world settings. New strategies are urgently needed to guide treatment discontinuation decisions. Blood-based biomarkers (BBMS), particularly plasma P-TAU217 and AΒ42, are promising tools that could reduce reliance on pet. The P-TAU217/AΒ42 ratio is FDA-approved to predict amyloid pet positivity, but BBMS have not been validated for monitoring treatment response or informing discontinuation decisions. The overarching goal of this project is to determine whether BBMS can serve as accurate surrogates for amyloid pet in patients receiving donanemab across four sites in northern california. Aim 1 will calibrate amyloid plaque clearance on pet against longitudinal BBM trajectories in 250 patients treated with donanemab. We hypothesize that changes in plasma P-TAU217 and AΒ42, individually or as a ratio, will predict amyloid clearance with >90% accuracy. Aim 2 will then test BBMS prospectively as a monitoring tool to identify patients likely to have cleared plaques, triggering confirmatory pet and discontinuation of treatment when appropriate. Importantly, blood samples will be banked, creating an enduring biorepository for future biomarker discovery. This will be the first clinical implementation study to evaluate BBMS in the context of disease-modifying therapies. The expected impact is substantial: reducing unnecessary pet scans, lowering healthcare costs, enhancing safety by minimizing prolonged drug exposure, optimizing infusion center capacity, and expanding equitable access to high-quality ad care. Beyond its immediate clinical value, the study will generate harmonized protocols and infrastructure to support future multi-site treatment monitoring efforts.

Quick answers

Who received award U01AG103014?

U01AG103014 was awarded to The Regents Of The University Of California. San Francisco by National Institute on Aging (National Institutes of Health) on September 9, 2026.

How much is award U01AG103014 worth?

$803,175 has been obligated on U01AG103014.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award